Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Calithera Biosciences, Inc"
Count: 22
Selected: 0
| NCT ID | Title |
|---|
| NCT02197572 | Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors | ||
| NCT05319028 | Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | ||
| NCT05275673 | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer | ||
| NCT03057600 | Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) | ||
| NCT04265534 | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | ||
| NCT03965845 | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | ||
| NCT03163667 | CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) | ||
| NCT02071862 | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | ||
| NCT04279769 | Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis | ||
| NCT03875313 | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | ||
| NCT04698681 | NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial | ||
| NCT03428217 | CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma | ||
| NCT02771626 | Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) | ||
| NCT04607512 | Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects | ||
| NCT04540965 | Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects | ||
| NCT02071888 | Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | ||
| NCT02071927 | Study of the Glutaminase Inhibitor CB-839 in Leukemia | ||
| NCT02944435 | A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults | ||
| NCT03097328 | Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | ||
| NCT03263429 | Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer | ||
| NCT05521997 | Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer | ||
| NCT04824937 | Telaglenastat + Talazoparib In Prostate Cancer |
